OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Glioma

IDH-mutant astrocytoma and oligodendroglioma, IDH inhibitors, and BRAF- and H3-altered tumours.

Live from Open Targets Platform, fetched 2026-11-12 09:16 UTC. Every row links to its source record.
Targets linked to glioma
12,706
the top 50 by overall evidence are shown
With inherited (germline) evidence
29
of the top 50, score above 0.1
Strong genetics, few drugs
39
genetic evidence 0.5 or more, drug evidence under 0.5
39 of the top 50 glioma targets have strong human genetic evidence but little drug evidence so far

Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.

Has inherited (germline) evidence above 0.1Tumour (somatic) or other evidence only
000.250.250.50.50.750.7511Drug evidence (trials and approvals) →Human genetic evidence →Genetics strong, few drugs: open betsGenetics strong, drugs in the clinicDrugs in the clinic, weaker geneticsLZTR1: genetic evidence 0.97 (germline 0.97, somatic 0.64), drug evidence 0.00TP53: genetic evidence 0.95 (germline 0.82, somatic 0.95), drug evidence 0.12IDH1: genetic evidence 0.92 (germline 0.24, somatic 0.92), drug evidence 0.93NF1: genetic evidence 0.94 (germline 0.92, somatic 0.94), drug evidence 0.00BRAF: genetic evidence 0.92 (germline 0.19, somatic 0.92), drug evidence 0.92SMARCB1: genetic evidence 0.85 (germline 0.85, somatic 0.72), drug evidence 0.00PTEN: genetic evidence 0.92 (germline 0.72, somatic 0.92), drug evidence 0.00NF2: genetic evidence 0.87 (germline 0.87, somatic 0.87), drug evidence 0.00H3-3A: genetic evidence 0.87 (germline 0.87, somatic 0.87), drug evidence 0.00IDH2: genetic evidence 0.89 (germline 0.89, somatic 0.84), drug evidence 0.92FGFR1: genetic evidence 0.85 (germline 0.00, somatic 0.85), drug evidence 0.38ATRX: genetic evidence 0.94 (germline 0.61, somatic 0.94), drug evidence 0.00EGFR: genetic evidence 0.86 (germline 0.55, somatic 0.86), drug evidence 0.64PIK3R1: genetic evidence 0.87 (germline 0.52, somatic 0.87), drug evidence 0.37PIK3CA: genetic evidence 0.87 (germline 0.00, somatic 0.87), drug evidence 0.37MAP2K2: genetic evidence 0.79 (germline 0.00, somatic 0.79), drug evidence 0.94RAF1: genetic evidence 0.71 (germline 0.00, somatic 0.71), drug evidence 0.88CIC: genetic evidence 0.89 (germline 0.00, somatic 0.89), drug evidence 0.00H3C2: genetic evidence 0.90 (germline 0.61, somatic 0.90), drug evidence 0.00CDKN2A: genetic evidence 0.83 (germline 0.18, somatic 0.83), drug evidence 0.00FUBP1: genetic evidence 0.86 (germline 0.00, somatic 0.86), drug evidence 0.00MAP2K1: genetic evidence 0.57 (germline 0.00, somatic 0.57), drug evidence 0.94PDGFRA: genetic evidence 0.79 (germline 0.00, somatic 0.79), drug evidence 0.57TERT: genetic evidence 0.86 (germline 0.86, somatic 0.69), drug evidence 0.08RB1: genetic evidence 0.85 (germline 0.00, somatic 0.85), drug evidence 0.00H3-3B: genetic evidence 0.87 (germline 0.87, somatic 0.57), drug evidence 0.00BRCA2: genetic evidence 0.80 (germline 0.80, somatic 0.70), drug evidence 0.00KMT2C: genetic evidence 0.84 (germline 0.00, somatic 0.84), drug evidence 0.00ACVR1: genetic evidence 0.83 (germline 0.00, somatic 0.83), drug evidence 0.00PPM1D: genetic evidence 0.83 (germline 0.00, somatic 0.83), drug evidence 0.00PTPN11: genetic evidence 0.77 (germline 0.61, somatic 0.77), drug evidence 0.00NOTCH1: genetic evidence 0.81 (germline 0.00, somatic 0.81), drug evidence 0.00ARID1A: genetic evidence 0.74 (germline 0.00, somatic 0.74), drug evidence 0.00KMT2D: genetic evidence 0.74 (germline 0.00, somatic 0.74), drug evidence 0.00FGFR3: genetic evidence 0.88 (germline 0.19, somatic 0.88), drug evidence 0.19CDKN2C: genetic evidence 0.75 (germline 0.00, somatic 0.75), drug evidence 0.00MUTYH: genetic evidence 0.84 (germline 0.84, somatic 0.60), drug evidence 0.00GSR: genetic evidence 0.00 (germline 0.00, somatic 0.00), drug evidence 0.96ARAF: genetic evidence 0.40 (germline 0.00, somatic 0.40), drug evidence 0.87CDKN2B: genetic evidence 0.84 (germline 0.84, somatic 0.00), drug evidence 0.00NBN: genetic evidence 0.65 (germline 0.28, somatic 0.65), drug evidence 0.00TSC2: genetic evidence 0.85 (germline 0.19, somatic 0.85), drug evidence 0.00FLCN: genetic evidence 0.84 (germline 0.44, somatic 0.84), drug evidence 0.00TSC1: genetic evidence 0.84 (germline 0.19, somatic 0.84), drug evidence 0.00ATM: genetic evidence 0.72 (germline 0.72, somatic 0.71), drug evidence 0.00SMARCA4: genetic evidence 0.73 (germline 0.19, somatic 0.73), drug evidence 0.00QKI: genetic evidence 0.73 (germline 0.00, somatic 0.73), drug evidence 0.00ERBB2: genetic evidence 0.69 (germline 0.61, somatic 0.69), drug evidence 0.20NTRK2: genetic evidence 0.86 (germline 0.00, somatic 0.86), drug evidence 0.14VEGFA: genetic evidence 0.00 (germline 0.00, somatic 0.00), drug evidence 0.86LZTR1TP53IDH1BRAFPTENNF2IDH2FGFR1EGFRPIK3R1MAP2K2RAF1MAP2K1PDGFRATERTPTPN11FGFR3ARAFNBNATMERBB2NTRK2

Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.

Where the genetics points and the pipeline has not gone yet

The 39 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.

LZTR1 0.97TP53 0.95PedsATRX 0.94PedsNF1 0.94PTEN 0.92PedsH3C2 0.90CIC 0.89FGFR3 0.88PIK3R1 0.87H3-3A 0.87NF2 0.87PIK3CA 0.87PedsH3-3B 0.87FUBP1 0.86TERT 0.86PedsNTRK2 0.86FGFR1 0.85TSC2 0.85SMARCB1 0.85RB1 0.85CDKN2B 0.84TSC1 0.84KMT2C 0.84FLCN 0.84MUTYH 0.84CDKN2A 0.83ACVR1 0.83PedsPPM1D 0.83PedsNOTCH1 0.81PedsBRCA2 0.80PTPN11 0.77PedsCDKN2C 0.75KMT2D 0.74ARID1A 0.74QKI 0.73SMARCA4 0.73ATM 0.72PedsERBB2 0.69PedsNBN 0.65

All 50 targets, by type of evidence

Ranked by overall score for glioma on the Open Targets Platform. Darker cells mean stronger evidence of that type.

Peds RMTLmarks the 18 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.

TargetOverallGermline geneticsSomaticLiteraturegenetic literatureClinicalAnimal modelsPathways
LZTR1
leucine zipper like post translational regulator 1
0.870.970.64
TP53Peds RMTL
tumor protein p53
0.850.820.95
IDH1Peds RMTL
isocitrate dehydrogenase (NADP(+)) 1
0.840.240.92
NF1
neurofibromin 1
0.830.920.94
BRAFPeds RMTL
B-Raf proto-oncogene, serine/threonine kinase
0.830.190.92
SMARCB1
SWI/SNF related BAF chromatin remodeling complex subunit B1
0.820.850.72
PTENPeds RMTL
phosphatase and tensin homolog
0.820.720.92
NF2
NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor
0.810.870.87
H3-3A
H3.3 histone A
0.800.870.87
IDH2Peds RMTL
isocitrate dehydrogenase (NADP(+)) 2
0.800.890.84
FGFR1
fibroblast growth factor receptor 1
0.77–0.85
ATRXPeds RMTL
ATRX chromatin remodeler
0.760.610.94
EGFRPeds RMTL
epidermal growth factor receptor
0.740.550.86
PIK3R1
phosphoinositide-3-kinase regulatory subunit 1
0.720.520.87
PIK3CAPeds RMTL
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
0.70–0.87
MAP2K2Peds RMTL
mitogen-activated protein kinase kinase 2
0.69–0.79
RAF1
Raf-1 proto-oncogene, serine/threonine kinase
0.69–0.71
CIC
capicua transcriptional repressor
0.69–0.89
H3C2
H3 clustered histone 2
0.680.610.90
CDKN2A
cyclin dependent kinase inhibitor 2A
0.670.180.83
FUBP1
far upstream element binding protein 1
0.66–0.86
MAP2K1Peds RMTL
mitogen-activated protein kinase kinase 1
0.66–0.57
PDGFRAPeds RMTL
platelet derived growth factor receptor alpha
0.66–0.79
TERTPeds RMTL
telomerase reverse transcriptase
0.660.860.69
RB1
RB transcriptional corepressor 1
0.66–0.85
H3-3B
H3.3 histone B
0.660.870.57
BRCA2
BRCA2 DNA repair associated
0.640.800.70
KMT2C
lysine methyltransferase 2C
0.64–0.84
ACVR1Peds RMTL
activin A receptor type 1
0.64–0.83
PPM1DPeds RMTL
protein phosphatase, Mg2+/Mn2+ dependent 1D
0.64–0.83
PTPN11Peds RMTL
protein tyrosine phosphatase non-receptor type 11
0.630.610.77
NOTCH1Peds RMTL
notch receptor 1
0.63–0.81
ARID1A
AT-rich interaction domain 1A
0.62–0.74
KMT2D
lysine methyltransferase 2D
0.61–0.74
FGFR3
fibroblast growth factor receptor 3
0.610.190.88
CDKN2C
cyclin dependent kinase inhibitor 2C
0.61–0.75
MUTYH
mutY DNA glycosylase
0.600.840.60
GSR
glutathione-disulfide reductase
0.59––
ARAF
A-Raf proto-oncogene, serine/threonine kinase
0.59–0.40
CDKN2B
cyclin dependent kinase inhibitor 2B
0.580.84–
NBN
nibrin
0.580.280.65
TSC2
TSC complex subunit 2
0.580.190.85
FLCN
folliculin
0.580.440.84
TSC1
TSC complex subunit 1
0.570.190.84
ATMPeds RMTL
ATM serine/threonine kinase
0.570.720.71
SMARCA4
SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4
0.570.190.73
QKI
QKI, KH domain containing RNA binding
0.57–0.73
ERBB2Peds RMTL
erb-b2 receptor tyrosine kinase 2
0.570.610.69
NTRK2
neurotrophic receptor tyrosine kinase 2
0.56–0.86
VEGFA
vascular endothelial growth factor A
0.56––

29 biomarkers in Glioma have validated or clinical evidence in CIViC

Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Glioma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 70 accepted items exist; the first 70 were read. This is the published evidence, not treatment advice.